Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of L-Citrulline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.45 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Citrulline SCHEMBL31672873 | 1.00 | OTC (0.48) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| L-Citrulline SCHEMBL319675 | 1.00 | OTC (0.48) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| L-Citrulline SCHEMBL13276387 | 0.98 | OTC (0.47) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| L-Citrulline SCHEMBL9056462 | 0.89 | OTC (0.51) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL9056465 | 0.89 | OTC (0.51) | OTCDDAH1GSRNOS2CYP1A2 | |
| Arginine SCHEMBL30193366 | 0.88 | OTC (0.46) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| Arginine SCHEMBL423591 | 0.88 | OTC (0.46) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| Arginine SCHEMBL21827041 | 0.88 | OTC (0.46) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| Arginine SCHEMBL423592 | 0.88 | OTC (0.46) | OTCSMN1; SMN2DDAH1GSRNOS2 | |
| L-Citrulline SCHEMBL215403 | 0.87 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107233-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR INCREASING NITRIC OXIDE IN A SUBJECT | LifeActive, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130850-A1 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | LIFEACTIVE INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4724101-A1 | TRANSDERMAL DELIVERY FORMULATIONS | Lifeactive, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090981-A1 | TRANSDERMAL DELIVERY FORMULATIONS | LifeActive, Inc. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260090982-A1 | TRANSDERMAL DELIVERY FORMULATIONS | LifeActive, Inc. (US) | 2026-04-02 | — | — | US | claimed |
| US-20250387319-A1 | Compositions and methods to reduce wrinkles, sagging skin, aging skin, spots, under eye puffiness and dark circles, and dry skin. | WU JOHN HAN (US) | 2025-12-25 | — | — | US | claimed |
| EP-3639666-B1 | USE OF LECITHINS AS A BIOCIDE AGAINST ARTHROPODS | MARTIN BRETONES GERMAN (ES) | 2025-12-17 | — | — | EP | claimed |
| US-20250223239-A1 | FOLIAR FEEDING FORMULATION AND METHODS OF USE | TYREE'S GREEN LLC | 2025-07-10 | — | — | US | claimed |
| US-20070248648-A1 | High protein, fatigue reducing powder | NEXT PROTEINS, INC. | 2007-10-25 | — | — | US | claimed |
| WO-2007106731-A2 | PROTEIN DRINK AND METHOD OF MAKING SAME | NEXT PROTEINS, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20070196511-A1 | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker | APLODAN FORMULATIONS LTD. (CA) | 2007-08-23 | — | — | US | claimed |
| US-20070154614-A1 | PROTEIN BEVERAGE AND METHOD OF MAKING THE SAME | DAVINAS, LLC | 2007-07-05 | — | — | US | claimed |
| US-20070148307-A1 | PROTEIN BEVERAGE AND PROTEIN BEVERAGE CONCENTRATE AND METHODS OF MAKING THE SAME | DAVINAS, LLC | 2007-06-28 | — | — | US | claimed |
| US-20070148305-A1 | PROTEIN BEVERAGE AND METHOD OF MAKING THE SAME | DAVINAS, LLC | 2007-06-28 | — | — | US | claimed |
| WO-2007027213-A1 | HIGH ENERGY CARBONATED PROTEIN DRINK AND METHOD OF MAKING | NEXT PROTEINS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20060147602-A1 | High energy carbonated protein drink and method of making | NEXT PROTEINS, INC. | 2006-07-06 | — | — | US | claimed |
| US-20060083793-A1 | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker | EVERSLIM FORMULATIONS LTD. (CA) | 2006-04-20 | — | — | US | claimed |
| WO-2006034586-A1 | NUTRITIONAL COMPOSITION FOR PROMOTING MUSCLE PERFORMANCE AND ACTING AS HYDROGEN (H+) BLOCKER | APLODAN FORMULATIONS LTD. (CA) | 2006-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060083793-A1 | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker | TNNC1, PYGM, MB | OTC 49/4885SMN1; SMN2 1491/4885DDAH1 1116/4885 |
| US-20260130850-A1 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CS, SUCNR1, SLC27A1 | OTC 5/4885SMN1; SMN2 856/4885DDAH1 3301/4885 |
| US-20260090981-A1 | TRANSDERMAL DELIVERY FORMULATIONS | CS, OAT, CKMT1A; CKMT1B | OTC 54/4885SMN1; SMN2 1078/4885DDAH1 4390/4885 |
| US-20260090982-A1 | TRANSDERMAL DELIVERY FORMULATIONS | CS, OAT, CKMT1A; CKMT1B | OTC 54/4885SMN1; SMN2 1078/4885DDAH1 4390/4885 |
| US-20250387319-A1 | Compositions and methods to reduce wrinkles, sagging skin, aging skin, spots, under eye puffiness and dark circles, and dry skin. | ARG2, ARG1, CUTA | OTC 100/4885SMN1; SMN2 3795/4885DDAH1 2413/4885 |
| US-20070196511-A1 | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker | TNNC1, PYGM, MB | OTC 49/4885SMN1; SMN2 1491/4885DDAH1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.